Clinical Approach and Emerging Therapeutics for Focal Segmental Glomerulosclerosis (FSGS)
_JPG.jpg)
Featuring a patient perspective on FSGS:
Will Wellman
Key Takeaway:
Focal Segmental Glomerulosclerosis (FSGS) is a rare but significant disease that has caused clinical confusion for decades. Fortunately, the past decade has yielded monumental progress in our understanding of its underlying mechanisms. With the landmark April 2026 FDA approval of sparsentan—the very first drug indicated specifically for FSGS—there has never been a more critical or perfect time for this course.
Because managing this evolving landscape requires seamless collaboration, this module specifically focuses on an interprofessional team approach to treating FSGS, leveraging the distinct and overlapping expertise of nephrologists and clinical pharmacists to optimize patient outcomes.
Learning Objectives:
-
Describe the pathophysiology of FSGS and differentiate between primary, secondary and genetic forms of FSGS.
-
Identify key diagnostic findings (UA, kidney biopsy, imaging studies) and the clinical presentation of FSGS (proteinuria, edema, hypertension)
-
Describe the existing and emerging treatment options for FSGS
-
Using a patient case, choose the appropriate therapy based on the clinical presentation and risks and benefits of therapy.
75 minutes
Disclosures:
The following planners and presenters have disclosed a financial relationship with an ineligible company:
-
Howard Trachtman, MD, Consultant [Akebia, Alentis, AstraZeneca, Biogen, Dimerix, Boehringer-Ingelheim, Eloxx, Novartis, Maze, Otsuka, Travere, Vera Therapeutics, Walden Biosciences, Unifor Bio, Apellis, Google Ventures]
-
Marisa Battistella, PharmD, Speaker's Bureau [Otsuka, Bayer.]
-
Calvin Meaney, PharmD, BCPS - Speaker's Bureau [GSK], Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
Accreditation Details
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for 1 hour AMA PRA Category 1.25 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded 1.25 contact hour of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for 1.25 contact hour. UAN: JA4008105-9999-26-055-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.